INTI Inhibitor Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1042418 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-188.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,373.4%
Debt / equity—
Current ratio0.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-21.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $0 |
| R&D expense | $1.70M | $1.76M | $1.38M | $6,150 | $4,905 |
| SG&A expense | $1.73M | $1.90M | $2.02M | $651,776 | $320,490 |
| Operating income | -$3.43M | -$3.66M | -$3.40M | -$657,926 | -$325,395 |
| Interest expense | — | — | — | $23,234 | $14,837 |
| Pretax income | — | — | -$3.03M | $12.16M | -$298,632 |
| Income tax | — | — | — | $55,109 | $0 |
| Net income | -$3.30M | -$3.34M | -$3.03M | $12.11M | -$298,632 |
| EPS (basic) | -0.02 | -0.02 | -0.02 | 0.03 | 0.00 |
| EPS (diluted) | -0.02 | -0.02 | -0.02 | 0.03 | 0.00 |
| Weighted avg. shares (diluted) | 172.51M | 172.26M | 171.95M | 366.18M | 376.25M |
| Banking | |||||
| Net interest income | — | — | — | — | -$14,837 |
| Balance sheet | |||||
| Cash & equivalents | $2.38M | $5.61M | $8.84M | $11.95M | $30,626 |
| Current assets | $2.45M | $5.69M | $8.95M | $11.98M | $58,784 |
| Total assets | $2.51M | $5.69M | $8.95M | $11.98M | $58,784 |
| Current liabilities | $766,330 | $709,618 | $665,164 | $678,782 | $679,630 |
| Short-term debt | $24,724 | — | — | — | — |
| Long-term debt | $36,889 | — | — | — | — |
| Total debt | $61,613 | — | — | — | — |
| Total liabilities | $3.80M | $3.71M | $3.67M | $3.68M | $3.68M |
| Shareholders' equity | -$1.29M | $1.99M | $5.28M | $8.30M | -$3.62M |
| Net debt | -$2.31M | — | — | — | — |
| Shares outstanding | 172.57M | 172.32M | 172.02M | 171.79M | 376.86M |
| Cash flow statement | |||||
| Operating cash flow | -$3.23M | -$3.23M | -$2.70M | $11.74M | -$220,433 |
| Financing cash flow | — | — | -$411,000 | $180,000 | $176,000 |
| Stock-based compensation | $23,385 | $40,250 | $13,784 | — | $37,990 |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.